# Michel Delforge

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michel-delforge/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,358 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 31 |
| i10-index | 68 |
| Last Known Institution | KU Leuven |
| OpenAlex ID | https://openalex.org/A5111810323 |
| Works | 310 |

## Researcher papers

- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study](https://scholariq.org/papers/non-invasive-detection-of-genomic-imbalances-in-hodgkin-reed-sternberg-cells-in/)
- [Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.](https://scholariq.org/papers/idecabtagene-vicleucel-ide-cel-bb2121-a-bcma-targeted-car-t-cell-therapy-in/)
- [HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)](https://scholariq.org/papers/hovon-65-gmmg-hd4-randomized-phase-iii-trial-comparing-bortezomib-doxorubicin/)
- [Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes](https://scholariq.org/papers/polyclonal-primitive-hematopoietic-progenitors-can-be-detected-in-mobilized/)
- [Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial](https://scholariq.org/papers/value-of-allogeneic-versus-autologous-stem-cell-transplantation-and-chemotherapy/)
- [Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients](https://scholariq.org/papers/prognostic-indicators-in-primary-plasma-cell-leukaemia-a-multicentre/)
- [Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial](https://scholariq.org/papers/analysis-of-patient-reported-experiences-up-to-2-years-after-receiving/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [KU Leuven](https://scholariq.org/institutions/ku-leuven/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.